Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1086783 | Le Pharmacien Hospitalier et Clinicien | 2015 | 10 Pages |
Abstract
From an analytical point of view, rate of analysis is satisfactory but the main limit of the method is the identification of the active substance only by its UV-visible spectral properties. So, discrimination between some drugs is not possible, i.e. for ifosfamide/cyclophosphamide, or vindesine/vinblastine or doxorubicine/daunorubicine. Moreover, monoclonal antibodies preparations cannot be analysed by FIA-DAD. Other devices available on the market (Multispec®, RXN1 analyser®, QcPrep) can compensate for these inadequacies but the investment is relatively expensive and can act as an obstacle to the control. In fact, new practices have to be considered.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology, Toxicology and Pharmaceutics (General)
Authors
B. (Interne en pharmacie), J. (Praticien hospitalier), N. Sobalak, H. Zenier, A. (Professeur des universités, praticien hospitalier),